These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35776322)

  • 21. VHH Nanobody Versatility against Pentameric Ligand-Gated Ion Channels.
    Nemecz D; Nowak WA; Nemecz Á
    J Med Chem; 2024 Jun; 67(11):8502-8518. PubMed ID: 38829690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progress in nanobody and its application in diagnosis].
    Kong Q; Yao Y; Chen R; Lu S
    Sheng Wu Gong Cheng Xue Bao; 2014 Sep; 30(9):1351-61. PubMed ID: 25720150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application Progress of the Single Domain Antibody in Medicine.
    Tang H; Gao Y; Han J
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanobodies: natural single-domain antibodies.
    Muyldermans S
    Annu Rev Biochem; 2013; 82():775-97. PubMed ID: 23495938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NanoBERTa-ASP: predicting nanobody paratope based on a pretrained RoBERTa model.
    Li S; Meng X; Li R; Huang B; Wang X
    BMC Bioinformatics; 2024 Mar; 25(1):122. PubMed ID: 38515052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.
    Hambach J; Mann AM; Bannas P; Koch-Nolte F
    Front Immunol; 2022; 13():1005800. PubMed ID: 36405759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Two-Step Approach for the Design and Generation of Nanobodies.
    Wagner HJ; Wehrle S; Weiss E; Cavallari M; Weber W
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation and characterization of nanobodies targeting GPCR.
    Zhang S; Fan Z; Liu J
    Biophys Rep; 2024 Feb; 10(1):22-30. PubMed ID: 38737476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.
    Jähnichen S; Blanchetot C; Maussang D; Gonzalez-Pajuelo M; Chow KY; Bosch L; De Vrieze S; Serruys B; Ulrichts H; Vandevelde W; Saunders M; De Haard HJ; Schols D; Leurs R; Vanlandschoot P; Verrips T; Smit MJ
    Proc Natl Acad Sci U S A; 2010 Nov; 107(47):20565-70. PubMed ID: 21059953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development by Genetic Immunization of Monovalent Antibodies (Nanobodies) Behaving as Antagonists of the Human ChemR23 Receptor.
    Peyrassol X; Laeremans T; Gouwy M; Lahura V; Debulpaep M; Van Damme J; Steyaert J; Parmentier M; Langer I
    J Immunol; 2016 Mar; 196(6):2893-901. PubMed ID: 26864035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors.
    Eichhoff AM; Börner K; Albrecht B; Schäfer W; Baum N; Haag F; Körbelin J; Trepel M; Braren I; Grimm D; Adriouch S; Koch-Nolte F
    Mol Ther Methods Clin Dev; 2019 Dec; 15():211-220. PubMed ID: 31687421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-expression of monoclonal nanobodies used in the preparation of HRP-conjugated second antibody.
    Ahmadvand D; Rahbarizadeh F; Vishteh VK
    Hybridoma (Larchmt); 2008 Aug; 27(4):269-76. PubMed ID: 18707545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Display Technologies for Generation of Ig Single Variable Domains.
    Bobkov V; van der Woning B; de Haard H
    Methods Mol Biol; 2018; 1827():129-144. PubMed ID: 30196495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies.
    Zavrtanik U; Lukan J; Loris R; Lah J; Hadži S
    J Mol Biol; 2018 Oct; 430(21):4369-4386. PubMed ID: 30205092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoreaction of a recombinant nanobody from camelid single domain antibody fragment with Acinetobacter baumannii.
    Payandeh Z; Rasooli I; Mousavi Gargari SL; Rajabi Bazl M; Ebrahimizadeh W
    Trans R Soc Trop Med Hyg; 2014 Feb; 108(2):92-8. PubMed ID: 24463583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation.
    Eden T; Menzel S; Wesolowski J; Bergmann P; Nissen M; Dubberke G; Seyfried F; Albrecht B; Haag F; Koch-Nolte F
    Front Immunol; 2017; 8():1989. PubMed ID: 29410663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The development of nanobodies for therapeutic applications.
    Van Bockstaele F; Holz JB; Revets H
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1212-24. PubMed ID: 19876789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs.
    Pinto-Espinoza C; Guillou C; Rissiek B; Wilmes M; Javidi E; Schwarz N; Junge M; Haag F; Liaukouskaya N; Wanner N; Nicke A; Stortelers C; Tan YV; Adriouch S; Magnus T; Koch-Nolte F
    Front Pharmacol; 2022; 13():1029236. PubMed ID: 36299894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of Nanobodies.
    Muyldermans S
    Annu Rev Anim Biosci; 2021 Feb; 9():401-421. PubMed ID: 33233943
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.